Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.80 +2.9%	$1.53	$0.99 ▼ $13.50	$91.34M	2.81	1.63 million shs	4.64 million shs
ORKA Oruka Therapeutics	$12.87 +2.1%	$10.16	$5.49 ▼ $31.13	$471.76M	-0.38	220,757 shs	138,587 shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.30 ▼ $6.65	$381.02M	0.9	3.46 million shs	N/A
SANA Sana Biotechnology	$2.54 -5.9%	$1.93	$1.26 ▼ $7.40	$572.71M	1.78	3.53 million shs	3.66 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	+2.86%	-17.43%	+36.36%	-1.10%	-85.20%
ORKA Oruka Therapeutics	+2.14%	+5.58%	+33.78%	+16.05%	+1,286,999,900.00%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	+20.66%
SANA Sana Biotechnology	-5.93%	-0.39%	+41.90%	-13.31%	-62.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.9015 of 5 stars	4.5	1.0	0.0	3.1	0.8	0.6
ORKA Oruka Therapeutics	3.0798 of 5 stars	3.6	0.0	0.0	3.8	2.5	0.6
RVNC Revance Therapeutics	2.6109 of 5 stars	3.1	0.0	4.7	0.0	1.7	0.6
SANA Sana Biotechnology	2.1535 of 5 stars	3.4	0.0	0.0	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$20.33	1,029.63% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	213.71% Upside
RVNC Revance Therapeutics	2.13	Hold	$8.45	131.51% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	325.20% Upside

Current Analyst Ratings Breakdown

Latest CABA, SANA, RVNC, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/15/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/1/2025	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
4/1/2025	CABA Cabaletta Bio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
4/1/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/1/2025	CABA Cabaletta Bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $22.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$5.51 per share	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$67.68M	-$2.54	N/A	N/A	N/A	N/A	-50.10%	-45.49%	8/6/2025 (Estimated)
ORKA Oruka Therapeutics	-$5.34M	-$4.51	N/A	N/A	N/A	N/A	-24.96%	-21.22%	7/30/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	8/6/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	8/6/2025 (Estimated)

Latest CABA, SANA, RVNC, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	8.11	8.11
ORKA Oruka Therapeutics	N/A	22.89	22.89
RVNC Revance Therapeutics	N/A	4.12	3.05
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
ORKA Oruka Therapeutics	56.44%
RVNC Revance Therapeutics	97.70%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
ORKA Oruka Therapeutics	24.69%
RVNC Revance Therapeutics	5.10%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	44.05 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable

CABA, SANA, RVNC, and ORKA Headlines

Recent News About These Companies

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's Why

June 11 at 4:42 PM | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?

June 10 at 2:14 PM | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 8, 2025 | marketbeat.com

Biggest Stocks in NASDAQ Featuring Sana Biotechnology and Kalkine

June 7, 2025 | kalkinemedia.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Raised by Two Sigma Advisers LP

June 6, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Millennium Management LLC

June 5, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Up 10.9% - Time to Buy?

June 4, 2025 | marketbeat.com

Bank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 4, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Voloridge Investment Management LLC

May 31, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

May 29, 2025 | marketbeat.com

Jane Street Group LLC Boosts Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

May 29, 2025 | marketbeat.com

Sana Biotechnology to Present at June 2025 Investor Conferences

May 28, 2025 | globenewswire.com

Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025

May 20, 2025 | accessnewswire.com

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 20, 2025 | globenewswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 20, 2025 | tmcnet.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky

May 20, 2025 | accessnewswire.com

SANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 20, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

May 20, 2025 | prnewswire.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025

May 20, 2025 | accessnewswire.com

SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

May 20, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, SANA, RVNC, and ORKA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.80 +0.05 (+2.86%)

As of 06/12/2025 04:00 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Oruka Therapeutics NASDAQ:ORKA

$12.87 +0.27 (+2.14%)

As of 06/12/2025 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)

As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Sana Biotechnology NASDAQ:SANA

$2.54 -0.16 (-5.93%)

As of 06/12/2025 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time